Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein in Breast Cancer

NCT07130162 | Not Yet Recruiting

• 1 other identifier: PIGU in breast cancer
• Study Type: observational
• Target: 96
• Locations: 0 countries
• Sites: N/A

Brief Summary

The present study aims to evaluate the serum level of PIGU protein in patients with breast cancer and its relation with clinical, laboratory and pathological data of the patients.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Detection of the serum level of PIGU protein in patients with breast cancer

  Evaluate the relation between serum level of PIGU protein in breast cancer patients and other clinical, laboratory and pathological data of the patients.

  baseline

Study Arms (2)

breast cancer patients

48 case

Diagnostic Test: Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)

healthy controls

48 case

Diagnostic Test: Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)

Interventions

Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA) DIAGNOSTIC_TEST

Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)

breast cancer patients; healthy controls

Eligibility Criteria

• Age: 18 Years - 80 Years
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

female patients who diagnosed as breast cancer based on pathological and radiological confirmation

You may qualify if:

• The study will be carried on female patients who diagnosed as breast cancer based on pathological and radiological confirmation, recruited from Clinical Oncology Departments and outpatient clinics, SECI, Assiut University

You may not qualify if:

• Patients diagnosed with other concomitant cancer.
• Patients who have already received chemotherapy or radiotherapy.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (5)

• An S, Liu F, Shi Y. Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer. Clin Chim Acta. 2025 Mar 1;569:120183. doi: 10.1016/j.cca.2025.120183. Epub 2025 Feb 6.

  PMID: 39922250 BACKGROUND

• Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1.

  PMID: 39352042 BACKGROUND

• Azim HA, Elghazawy H, Ghazy RM, Abdelaziz AH, Abdelsalam M, Elzorkany A, Kassem L. Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2023 Mar;9:e2200387. doi: 10.1200/GO.22.00387.

  PMID: 36888929 BACKGROUND

• Thakur N, Singh R, Sunigdha, Devgan R, Sharma A. Clinicopathological prognostic factors for survival in patients with breast cancer: a retrospective study from a tertiary cancer centre from North-West India. Ecancermedicalscience. 2025 Mar 6;19:1865. doi: 10.3332/ecancer.2025.1865. eCollection 2025.

  PMID: 40492224 BACKGROUND

• Wei X, Yang W, Zhang F, Cheng F, Rao J, Lu L. PIGU promotes hepatocellular carcinoma progression through activating NF-kappaB pathway and increasing immune escape. Life Sci. 2020 Nov 1;260:118476. doi: 10.1016/j.lfs.2020.118476. Epub 2020 Sep 21.

  PMID: 32971102 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Esraa gamal neyaz, Resident doctor

CONTACT

+20-01020731418; esraagamalneyaz2798@gmail.com

Noha Gaber Sayed, Prof. Dr

CONTACT

+20-01003305354; Noha.gaber@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: August 12, 2025
• First Posted: August 19, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: August 19, 2025

Record last verified: 2025-08